The LP-PLA2 is usually used as a biomarker for diagnosing cardiovascular disease (CVD)19, and many studies in human beings have proven that CVD and NAFLD were associated each other. Here, PLA2G7 is linked to metabolic dysfunction-associated steatotic liver disease.